- Mean health-related QoL (HRQoL) scores were maintained after initiation of treatment with apalutamide in patients with nonmetastatic castration-resistant prostate cancer (CRPC).
- A trend toward HRQoL deterioration from baseline was noted with placebo.
Why this matters
- Apalutamide extended metastasis-free survival in
SPARTANin these patients.
- QoL data further support the addition of apalutamide to current standard of care in this setting.
- Exploratory analysis from the phase 3 double-blind SPARTAN trial that evaluated 1207 patients with nonmetastatic CRPC and PSA doubling time ≤10 months, randomly assigned 2:1 to receive apalutamide or placebo.
- Functional Assessment of Cancer Therapy-Prostate and -General (FACT-P and FACT-G) patient-reported outcome questionnaire and EuroQol 5-dimension, 3-level questionnaire (EQ-5D-3L) were used.
- Funding: Janssen Research & Development.
- Patient-reported outcomes were reported for 29 cycles and 25.8 months from treatment initiation.
- Median follow-up for OS, 20.3 months.
- Group mean patient-reported outcome scores showed FACT-P total score, FACT-G score, FACT-P subscale score, and EQ-5D-3L were maintained from baseline and did not change over time in patients receiving apalutamide vs placebo.
- Least-squares mean change from baseline showed that with placebo, there was a greater decrease in FACT-P total score, FACT-G score, FACT-P subscale score, and EQ-5D-3L vs apalutamide.
- Missing data.